ClinicalTrials.gg
Status unknownNCT04867720STELLAUpdated Apr 30, 2021

Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients

A Phase 4 interventional study of Everolimus in Liver Transplant, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

To evaluate the efficacy and safety of CertiroBell® tablet plus tacrolimus

Read the detailed description

This study is multi-center, single arm, open-label, phase 4 study to evaluate the efficacy and safety of CertiroBell® tablet plus tacrolimus in primary living donor liver transplant recipients.

02

Conditions studied

  • Liver Transplant

Keywords

  • Everolimus
  • CertiroBell
  • Tacrolimus
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who had liver transplantation from living donor and had passed over 3 months since operation.
  2. Over 20 years old
  3. Patients who are being treated with Tacrolimus at screening visit
  4. Patients who agreed to written

Exclusion criteria

Exclusion Criteria:

  1. Patients who had received non-liver organs before liver transplantation or had received other organs while receiving liver.
  2. Patients who had auxiliary partial orthotopic liver transplantation or had bioartifical liver
  3. Patients who have been diagnosed with acute rejection within 6 months and have been treated
  4. Patients who had hepatic artery complication such as hepatic artery thrombosis within recent 6 months
  5. Patients who have been diagnosed with malignant tumor within 5 years(however, the following will be excepted)

    • fully recovered from skin cancer(squamous cell/basal cell carcinoma or thyroid cancer)
    • haptocellular carcinoma without main vessel invasion
  6. Patients with severe systemic infection
  7. Patients who are difficult to communicate due to mental disorder
  8. Patients who are in treatment for hapatitis, or are over 3 times higher than upper normal limit in liver function test(T-, , ALT) or over 5 times higher than normal limit of ALP
  9. Patients who are(at screening visit)

    • WBC\<1,500/mm\^3
    • \<30,000/mm\^3
    • over 1.0 in Protein/creatinine ratio(UA test)
    • \<30mL/min/1.73m\^2(MDRD)
    • Total Cholesterol>350mg/dL or Triglycerides>500mg/dL
  10. Patients taking (hapatitis C virus) therapeutic drug or anti-HCV positive patients who have positive result in HCV RNA test at screening visit
  11. Patients who had plasmapheresis within 1 week
  12. Those who are pregnant, nursing, or are not practicing with appropriate method
  13. Patients who had plasmapheresis within 3 months
  14. if participated in other trail within 4 weeks(28 days)
  15. In investigator's judgement
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    CertiroBell Tablet

    Use in combination with Tacrolimus at least 6 months after liver transplantation.

    Drug: Everolimus

Interventions

  • - Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.

    Also known as: CertiroBell Tab.

06

What researchers measure

Primary outcomes

  1. Incidence of composite efficacy failure

    composite efficacy failure include biopsy-confirmed acute rejection, graft loss, death, or follow-up failure

    Time frame: until 24 weeks after taking medicine

Secondary outcomes

  1. Incidence of biopsy-confirmed acute rejection

    acute rejection confirmed by result of biopsy(over 4 points of RAI score)

    Time frame: until 24 weeks after taking medicine

  2. Pathological result, time of occurrence, treatment method and treatment result of acute rejection confirmed by biopsy(over 4 points of RAI score)

    details of acute rejection confiremd by result of biopsy(over 4 points of RAI score)

    Time frame: until 24 weeks after taking medicine

  3. Survival rate of patients

    Survival rate of patients

    Time frame: until 24 weeks after taking medicine

  4. Survival rate of transplanted organ

    Survival rate of transplanted organ

    Time frame: until 24 weeks after taking medicine

  5. Incidence rate of liver cancer

    Incidence rate of liver cancer

    Time frame: until 24 weeks after taking medicine

  6. Recurrence rate of liver cancer

    Recurrence rate of liver cancer

    Time frame: until 24 weeks after taking medicine

  7. Incidence rate of CMV infection

    Incidence rate of CMV infection

    Time frame: until 24 weeks after taking medicine

  8. Variation of serum creatinine, eGFR(estimated glomerular filtration rate) compared to baseline using MDRD(Modification of Diet in Renal Disease)

    eGRF using MDRD(Modification of Diet in Renal Disease) method

    Time frame: until 24 weeks after taking medicine

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hosipital
    Seoul, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Oct 2022, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
Apr 30, 2021
StartActual
Mar 16, 2021
Primary completionEst.
Oct 10, 2022
CompletionEst.
Feb 22, 2023
Last update
Apr 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04867720
Responsible party
Sponsor
First posted
Apr 30, 2021
Start date
Mar 16, 2021
Primary completion
Oct 10, 2022 (estimated)
Completion
Feb 22, 2023 (estimated)
Last update
Apr 30, 2021

Study contacts

Kyung-Suk Suh, M.D., Ph.D.
Contact
kssuh@snu.ac.kr
82-2-2072-7200
Kyung-Suk Suh, M.D., Ph.D.
study chair · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion